Patients' characteristics of miRNA screening cohort
| . | Negative for feature, n/% . | Positive for feature, n/% . |
|---|---|---|
| Thymidine kinase (> 10 U/L) | 34/50 (68.0%) | 16/50 (32.0%) |
| CD38 (> 10% positive CLL cells) | 34/50 (68.0%) | 16/50 (32.0%) |
| ZAP70 (> 20% positive CLL cells) | 25/50 (50.0%) | 25/50 (50.0%) |
| IgVH hypermutational status (homology > 98%) | 20/31 (64.5%) | 11/31 (35.4%) |
| . | Negative for feature, n/% . | Positive for feature, n/% . |
|---|---|---|
| Thymidine kinase (> 10 U/L) | 34/50 (68.0%) | 16/50 (32.0%) |
| CD38 (> 10% positive CLL cells) | 34/50 (68.0%) | 16/50 (32.0%) |
| ZAP70 (> 20% positive CLL cells) | 25/50 (50.0%) | 25/50 (50.0%) |
| IgVH hypermutational status (homology > 98%) | 20/31 (64.5%) | 11/31 (35.4%) |
Molecular features of 50 patients being diagnosed with CLL were assessed before miRNA profiling was performed.